10/18/2024

Janusmed sex and gender

Janusmed sex and gender – linaclotide

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Linaclotide

Linaclotide

Class : A

Show all info

Print

Contact us

  1. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(4):544-558.

  2. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196-206.

  3. Constella (linaclotide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-03-21, cited 2019-06-04].

  4. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12.

  5. Constella (linaclotide). EPAR Public assessment report [updated 2012-09-20, cited 2019-06-04].

  6. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS et al. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Gastroenterol. 2018;113(1):105-114.

  7. Food and Drug Administration (FDA). NDA Review - Linzess (linaclotide) capsules. Drugs@FDA [www]. [updated 2017-01-25, cited 2019-06-04].

  8. Food and Drug Administration (FDA). Summary Review - Linzess (linaclotide) Capsules. Drugs@FDA [www]. [updated 2012-10-04, cited 2019-06-04].

  9. Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019;13(4):397-406.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]

  1. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(4):544-558.
  2. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196-206.
  3. Constella (linaclotide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-03-21, cited 2019-06-04].
  4. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12.
  5. Constella (linaclotide). EPAR Public assessment report [updated 2012-09-20, cited 2019-06-04].
  6. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS et al. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Gastroenterol. 2018;113(1):105-114.
  7. Food and Drug Administration (FDA). NDA Review - Linzess (linaclotide) capsules. Drugs@FDA [www]. [updated 2017-01-25, cited 2019-06-04].
  8. Food and Drug Administration (FDA). Summary Review - Linzess (linaclotide) Capsules. Drugs@FDA [www]. [updated 2012-10-04, cited 2019-06-04].
  9. Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019;13(4):397-406.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]